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373* Non-adherence as coping strategy of young adult patients with
CF. A qualitative study
G.R. Seitz1, K. Mo¨rtl2, M. Leichsenring1, J. von Wietersheim2. 1Cystic Fibrosis
Center, Children’s Hospital, University of Ulm, Ulm, Germany; 2Department of
Psychosomatic Medicine and Psychotherapy, University of Ulm, Ulm, Germany
Objectives: Lack of adherence is not only an essential reason for deterioration of the
physical state of CF-patients, it also interferes with the caregiver-patient relationship
and is frequently seen as irrational, incomprehensible and dysfunctional behaviour.
Our study aims to understand relevant attitudes and experiences of young adult
CF-patients with respect to coping behaviour and caregiver-patient relationship and
to explore the relation between these factors and treatment adherence.
Methods: 12 semi-structured interviews were performed with patients (age
17−24 years). The interviews were audio-taped, transcripted and evaluated. Data
analysis was computer-aided by the ATLAS.ti software.
Findings: The study reveals a lot of clinically relevant information; e.g., avoiding
the treatment (taking medicine, visiting the doctor, diagnostics, . . . ) serves as a
function to avoid the burdening realisation of (the extend of) the illness. E.g. Going
to the hospital regularly is indeed a conﬁrmation that I’m in a bad shape . . . that’s
something I don’t want.
In fact, the relationship to the caregivers was shown to be a very supporting and
moderating factor to handle these burdening feelings; e.g. patients over all desire
respect, solicitousness and encouragement.
Conclusions: The ﬁndings provide a better comprehension of emotional aspects
concerning non-adherence. Non-adherence to medical treatment is not only a
dysfunctional behaviour but can be very reasonable to sustain emotional well
being. This strengthens the importance of the psychological and social role of
the caregivers and reveals signiﬁcant clues how to support our patients better and
to improve treatment adherence.
Supported by: Novartis.
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Background: Encouraging patients with a chronic disease such as CF to actively
manage their own condition may be effective, especially during adolescence when
adherence to treatment can diminish.
Aim: To facilitate self-management, via a mentorship system which develops
relationships between patients with CF and their health professionals, augmented
by telephone and IT tools, aiming to improve quality of life.
Method: A randomized, controlled pilot study of an education and behavioural
adaptation program designed to enhance self-management in adolescents aged
12−19 with CF. 46 participants were randomised to 1 of 3 groups for 6 months with
a further 6 months follow up: standard care (controls; N = 15), standard care + phone
mentoring (M; N= 16), or standard care, phone mentoring + IT tool (M+ IT; N= 15)
which facilitated electronic self reporting of daily symptoms. Primary outcomes
included the Stanford Self-Efﬁcacy scale and CFQ-R. Secondary outcomes were
spirometry and height and weight z-scores. Outcomes were re-assessed at 3, 6, and
12 months. Qualitative data were also collected from 10 intervention participants
and mentors.
Results: No clinically meaningful improvements were detected between groups.
Conclusions: The trial provided an important opportunity for mentor training and
reﬁnement of IT tools, but did not produce short-term improvements in these
particular outcomes for adolescents measured using these methods.
Supported by: CF Australia & RCHF Brisbane.
375 The Use of Patient Held Drug Information Cards to improve
adherence: a questionnaire survey
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Introduction: We have previously presented a pilot study of the use of these
drug information cards at the ECF, Prague 2008 (Journal of Cystic Fibrosis 2008;
7(Suppl 2):S102). The previous study showed that the drug cards were found to
be useful in educating our CF patients. In this study we developed the use of these
cards in CF patients perceived to have poor compliance with medication, or who
had recently joined the service (transition and new diagnosis).
Study design: We performed a questionnaire, comparing different responses in
the patient group perceived to have poor compliance, compared to those who had
newly joined the team (new diagnosis or transition), or those who had been given
the cards at the general CF clinic. The aim of this study was to see if there were
different perceptions of these cards by patients in these different patient groups.
Method: We developed a series of small (9 x 5 cm) cards which included simple,
relevant information about 11 of the commonly used CF drugs. This information
was tailored to the use of each medication in Cystic Fibrosis. The Drugs included:
Pulmozyme, Creon, Alendronate, Azithromycin, Colistin, Flu Vaccine, Insulin,
Omeprazole, Salbutamol Inhaler, Seretide Inhaler and Ursodeoxycholic Acid. The
cards were designed to provide concise information delivered in terminology that
was easily understandable and relevant to CF, and was not intended to replace the
package insert information. The drug information cards were introduced to CF
patients during outpatient visits, home visits and in-patient stays. The patients were
then surveyed 6 weeks after initial use of these cards and asked about their views
related to aiding compliance and education.
Results: The results of the questionnaire survey will be presented.
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Background: TIVADs are commonly used in children with CF with difﬁcult venous
access and a number of studies have demonstrated safety and a reasonable functional
lifespan in such subjects. However there are limited data reporting how children
with CF perceive their TIVAD.
Aims: To determine what children and adolescents with CF think about their TIVAD
and how having such a device affects their quality of life.
Methods: Families of twenty children with CF attending the Leeds Paediatric CF
Centre who had a TIVAD (either PORT-A-CATH® or P.A.S. PORT®) inserted
between 1993 and 2006 were invited to participate. A structured questionnaire was
answered by the child/adolescent, with parental help if required.
Results: 20 children with mean age 11.6 years (range 4−16 years) participated
(9 male). All 20 subjects reported that having a TIVAD had improved their quality
of life. 7 (35%) reported that having a TIVAD affected what clothes they chose
to wear, and 14 (70%) described that the TIVAD did sometimes cause pain or
discomfort. 5 (25%) reported that the TIVAD affected their body image or caused
embarrassment. 4 (20%) reported difﬁculty wearing a seat belt, and 2 (10%) that
the TIVAD affected their sleep.
Conclusions: Children and adolescents with cystic ﬁbrosis who have required
TIVAD insertion all report that the device improved their quality of life. This is
despite the majority reporting that the TIVAD sometimes caused pain or discomfort,
and commonly affected clothing choices. This information will be of use when
counselling children, adolescents, and their parents prior to TIVAD insertion.
